SRI developed halofantrine for the U.S. Army from 1965 to 1975 as a treatment for drug-resistant malaria. Distributed by the World Health Organization (WHO), the drug has saved countless lives. The Food and Drug Administration (FDA) approved halofantrine as an antimalarial in 1992 under the SmithKline Beecham (now GlaxoSmithKline) brand name, Halfan®.
Malaria treatment: Halofantrine
Read more from SRI
-
An SRI collaboration aims to improve online education for college students
The Postsecondary Teaching with Technology Collaborative aims to strengthen teaching and learning, improve student outcomes, and reduce societal gaps.
-
Exploring the American Dream: A Lively Discussion on Innovation and Progress
Watch the video: A conversation with SRI’s David Parekh and David Leonhardt of the New York Times.
-
Patrick Lincoln named new President of SRI’s Information & Computing Sciences division
The industry veteran and SRI Fellow brings deep knowledge across an array of technical disciplines.